List view / Grid view
8 December 2015 | By Victoria White
Doctors are harnessing patients’ own immune systems in a pioneering trial taking place in London in an effort to find a new effective treatment for resistant head and neck cancer...
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
8 December 2015 | By Victoria White
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate...
7 December 2015 | By Victoria White
Parkinson’s disease researchers at the University at Buffalo have developed a way to ramp up the conversion of skin cells into dopamine neurons...
7 December 2015 | By Victoria White
The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...
7 December 2015 | By Victoria White
Betalutin is the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL)...
4 December 2015 | By Victoria White
The researchers made the discovery using mice modified to carry the same mutation as people born without Nav1.7. Their research revealed that people who lack Nav1.7 also produce higher than normal levels of natural opioid peptides...
4 December 2015 | By Victoria White
ICR scientists have discovered Brf2 acts as a ‘master switch’ within cancer cells that seems to override the normal stress response...
4 December 2015 | By Victoria White
By the end of 2015, Baxalta says it expects to employ approximately 500 individuals at the Global Innovation Centre...
3 December 2015 | By Victoria White
Researchers say nanobombs might overcome a biological barrier that has blocked development of agents that work by altering the expression of genes in cancer cells...
3 December 2015 | By Victoria White
Morphotek has teamed up with UW-Madison to investigate the immunosuppressive effects of CA125 on farletuzumab...
3 December 2015 | By Victoria White
Preclinical testing demonstrated that the new antibodies work as a prophylaxis to provide short-term immunity and as a treatment to accelerate recovery...
3 December 2015 | By Victoria White
Using cell cultures of melanoma, researchers showed that these acid ceramidase inhibitors make melanoma cells more prone to be killed...
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
